DBVTF News and Press, Dbv Techs Boulogne Bill From 06/16/23

Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR ...

Montrouge, France, June 8, 2023 DBV Technologies to Participate i n Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming particip...

Montrouge, France, May 10, 2023 DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial D ata E valuating Viaskin™ Peanut in Toddlers Th e New England Journal of Medicine (NEJM) pu...

Montrouge, France, May 4, 2023 DBV Tech nolo gies Reports First Quarter 2023 Financial Results DBV closes Q1 2023 with cash and cash equivalents of $192.3 million . DBV Technologies (Euronext: DBV – ISIN: FR0010417345 ...

Montrouge, France, April 19, 2023 D BV Technologies Outlin es Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA The FDA confirmed that the Company’s Phase 3 EPITOPE study met the pre-specif...

Montrouge, France, April 12, 2023 DBV Technologies Announces Results of its 202 3 Ordinary and Extraordinary General Meeting Shareholders A pprove d A ll P roposed R esolutions DBV Technologies (Euronext: DBV – ISIN: FR001...

2023-04-03 08:55:13 ET Summary In December of 2022 I introduced a number of stocks which I was adding to my "Tax Loss Selling Basket". In this article I summarize the logic and criteria for the basket. I then tally up the results including calculating overall returns and looki...

Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock M...

Montrouge, France, March 13, 2023 DBV Technologies Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, informs its investors that it does not hold cash deposits or securities at Silicon Valle...

Montrouge, France, March 7, 2023 DBV Technologies Announces First Patient Screen ed in VITESSE Phase 3 Clinical Trial in Peanut - Allergic Children 4 – 7 Years Old First patient screened at Midwest Allergy Sinus Asthma in Normal, Illino...